Pharmacotherapy of obesity: Clinical treatments and considerations

American Journal of the Medical Sciences

Volumn 345, Issue 4, 2013, Pages 284-288

  Holes Lewis, Kelly Anne ^a,b   Malcolm, Robert ^a   O'neil, Patrick M ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Diabetes; Metabolism; Obesity; Pharmacotherapy of obesity; Weight loss

Indexed keywords

AMFEBUTAMONE; DEXFENFLURAMINE; FENFLURAMINE; GLUCOSE; LORCASERIN; NALTREXONE; PHENTERMINE PLUS TOPIRAMATE; RIMONABANT; SIBUTRAMINE;

ANXIETY; BACKACHE; BLOOD PRESSURE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; COGNITIVE DEFECT; COMORBIDITY; CONFERENCE PAPER; CONSTIPATION; COUGHING; DIET RESTRICTION; DIZZINESS; DRUG INDUCED HEADACHE; DRUG USE; DRUG WITHDRAWAL; FATIGUE; FOLLOW UP; GALACTORRHEA; GLUCOSE BLOOD LEVEL; GYNECOMASTIA; HEALTH; HEART INJURY; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSOMNIA; MEDICAL HISTORY; MOOD DISORDER; NONHUMAN; OBESITY; POSTPRANDIAL STATE; SIDE EFFECT; SUICIDAL IDEATION; WEIGHT REDUCTION; WELLBEING; XEROSTOMIA;

EID: 84876186731     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31828abcfd     Document Type: Conference Paper

References (19)

1. Behavioral Risk Factor Surveillance System. CDC. Available at: http://www.cdc.gov/obesity/data/adult.html.
2. Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet 2011;378:804-14.
3. Gupta AK, Greenway FL. Safety of Obesity Drugs. Section V. In: Bagchi D, Preuss HG, editors. Boca Raton, Florida: CRC Press, Taylor and Francis Group. Obesity: Epidemiology, Pathophysiology and Prevention, 2nd ed. 2012.
4. National Heart, Lung, and Blood Institute. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: the Evidence Report. Bethesda (MD): US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 1998. Available at http://www.nhlbi.nih. gov/guidelines/obesity/ob-gdlns.htm. Accessed July 20, 2010.
5. Malcolm R, O'Neil PM, Sexauer JD, et al. A controlled trial of naltrexone in obese humans. Int J Obes 1985;9:347-53.
6. Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 2009;17:30-9.
7. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011;19:110-20.
8. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595-605.
9. Arena Pharmaceuticals. 2012. Belviq Package Insert Information. Available at: http://us.eisai.com/package-inserts/BelviqPI.pdf. Accessed March 8, 2013.
10. Vivus Inc. 2012. Qsymia Package Insert Information. Available at: http://www.vivus.com/docs/QsymiaPI.pdf. Accessed March 8, 2013.
11. FDA News Release. FDA Approves Belviq to Treat Some Overweight or Obese Adults. Press announcement. 2012. Available at: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm309993.htm. Accessed March 8, 2013.
12. Halford JC, Harrold JA, Boyland EJ, et al. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007;67:27-55.
13. O'Neil PM, Smith SR, Weissman NJ, et al. Randomized placebocontrolled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM Study. Obesity 2012;20:1426-36.
14. Smith SR, Weissman NJ, Anderson CM, et al. Behavioral modification and Lorcaserin for overweight and obesity management (BLOOM) study group. Multicenter, placebo-controlled trial of Lorcaserin for weight management. N Engl J Med 2010;363:245-56.
15. Fidler MC, Sanchez M, Raether B, et al; for the BLOSSOM Clinical Trial Group. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab 2011;96:3067-77.
16. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlledrelease, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341-52.
17. Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity 2011;20:330-42.
18. Margulis AV, Mitchell AA, Gilboa SM, et al. National birth defects prevention study. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol 2012;207:405.e1-7.
19. Colman E, Golden J, Roberts M, et al. The FDA's assessment of two drugs for chronic weight management. N Engl J Med 2012;367:1577-9.